Gilead Sciences Inc Financials

GILD

Export CSV

Key Financial Metrics

Revenue

$28.8B

YoY+6.0%

5Y CAGR+5.1%

10Y CAGR+1.5%

Gilead Sciences Inc generated $28.8B in revenue in fiscal year 2024. This represents an increase of 6.0% from the prior year.

EBITDA

$4.4B

YoY-56.7%

5Y CAGR-0.4%

10Y CAGR-11.7%

Gilead Sciences Inc's EBITDA was $4.4B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.7% from the prior year.

Free Cash Flow

$10.3B

YoY+38.9%

5Y CAGR+4.4%

10Y CAGR-1.7%

Gilead Sciences Inc generated $10.3B in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents an increase of 38.9% from the prior year.

Net Income

$480.0M

YoY-91.5%

5Y CAGR-38.3%

10Y CAGR-27.6%

Gilead Sciences Inc reported $480.0M in net income in fiscal year 2024. This represents a decrease of 91.5% from the prior year.

EPS (Diluted)

N/A

Cash & Debt

N/A

Dividends Per Share

$3.08

YoY+2.7%

5Y CAGR+4.1%

Gilead Sciences Inc paid $3.08 per share in dividends in fiscal year 2024. This represents an increase of 2.7% from the prior year.

Shares Outstanding

1.25B

YoY+0.0%

5Y CAGR-0.3%

10Y CAGR-1.8%

Gilead Sciences Inc had 1.25B shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Gross Margin

78.3%

YoY+2.2pp

5Y CAGR-0.9pp

10Y CAGR-6.5pp

Gilead Sciences Inc's gross margin was 78.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.2 percentage points from the prior year.

Operating Margin

5.8%

YoY-22.3pp

5Y CAGR-13.3pp

10Y CAGR-55.5pp

Gilead Sciences Inc's operating margin was 5.8% in fiscal year 2024, reflecting core business profitability. This is down 22.3 percentage points from the prior year.

Net Margin

1.7%

YoY-19.2pp

5Y CAGR-22.3pp

10Y CAGR-47.0pp

Gilead Sciences Inc's net profit margin was 1.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 19.2 percentage points from the prior year.

Return on Equity

2.5%

YoY-22.4pp

5Y CAGR-21.3pp

10Y CAGR-74.0pp

Gilead Sciences Inc's return on equity was 2.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 22.4 percentage points from the prior year.

R&D Spending

$5.9B

YoY+3.3%

5Y CAGR+7.8%

10Y CAGR+7.5%

Gilead Sciences Inc invested $5.9B in research and development in fiscal year 2024. This represents an increase of 3.3% from the prior year.

Share Buybacks

$1.1B

YoY+15.0%

5Y CAGR-8.0%

10Y CAGR-14.2%

Gilead Sciences Inc spent $1.1B on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 15.0% from the prior year.

Capital Expenditures

$523.0M

YoY-10.6%

5Y CAGR-8.7%

10Y CAGR-0.6%

Gilead Sciences Inc invested $523.0M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 10.6% from the prior year.

GILD Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$28.8B+6.0%	$27.1B-0.6%	$27.3B-0.1%	$27.3B+10.6%	$24.7B+10.0%	$22.4B
Cost of Revenue	$6.3B-3.8%	$6.5B+14.9%	$5.7B-14.3%	$6.6B+44.4%	$4.6B-2.2%	$4.7B
Gross Profit	$22.5B+9.1%	$20.6B-4.7%	$21.6B+4.4%	$20.7B+2.9%	$20.1B+13.2%	$17.8B
R&D Expenses	$5.9B+3.3%	$5.7B+14.9%	$5.0B+8.2%	$4.6B-6.6%	$4.9B+21.5%	$4.1B
SG&A Expenses	$6.1B0.0%	$6.1B+7.4%	$5.7B+8.1%	$5.2B+1.8%	$5.2B+17.6%	$4.4B
Operating Income	$1.7B-78.1%	$7.6B+3.8%	$7.3B-26.1%	$9.9B+143.6%	$4.1B-5.0%	$4.3B
Interest Expense	$977.0M+3.5%	$944.0M+1.0%	$935.0M-6.6%	$1.0B+1.7%	$984.0M-1.1%	$995.0M
Income Tax	$211.0M-83.1%	$1.2B-0.1%	$1.2B-39.9%	$2.1B+31.5%	$1.6B+874.5%	-$204.0M
Net Income	$480.0M-91.5%	$5.7B+23.4%	$4.6B-26.2%	$6.2B+4961.0%	$123.0M-97.7%	$5.4B
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$7.8B+9.7%	$7.1B+6.2%	$6.7B	N/A	$7.5B+8.5%	$7.0B+4.0%	$6.7B	N/A
Cost of Revenue	$1.6B+4.5%	$1.5B-2.5%	$1.5B	N/A	$1.6B+1.9%	$1.5B-0.5%	$1.6B	N/A
Gross Profit	$6.2B+11.1%	$5.6B+8.9%	$5.1B	N/A	$6.0B+10.4%	$5.4B+5.4%	$5.1B	N/A
R&D Expenses	$1.3B-9.7%	$1.5B+8.1%	$1.4B	N/A	$1.4B+3.3%	$1.4B-11.1%	$1.5B	N/A
SG&A Expenses	$1.4B-0.6%	$1.4B+8.5%	$1.3B	N/A	$1.4B+4.1%	$1.4B+0.1%	$1.4B	N/A
Operating Income	$3.3B+34.5%	$2.5B+10.6%	$2.2B	N/A	$888.0M-66.4%	$2.6B+161.2%	-$4.3B	N/A
Interest Expense	$256.0M+0.8%	$254.0M-2.3%	$260.0M	N/A	$238.0M+0.4%	$237.0M-6.7%	$254.0M	N/A
Income Tax	$589.0M+25.9%	$468.0M+40.1%	$334.0M	N/A	-$297.0M-167.8%	$438.0M+239.0%	-$315.0M	N/A
Net Income	$3.1B+55.7%	$2.0B+49.0%	$1.3B	N/A	$1.3B-22.4%	$1.6B+138.7%	-$4.2B	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GILD Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$59.0B-5.0%	$62.1B-1.7%	$63.2B-7.0%	$68.0B-0.7%	$68.4B+11.0%	$61.6B
Current Assets	$19.2B+19.2%	$16.1B+11.4%	$14.4B-2.2%	$14.8B-7.7%	$16.0B-47.2%	$30.3B
Cash & Equivalents	N/A	N/A	$5.4B+1.4%	$5.3B-11.0%	$6.0B-48.4%	$11.6B
Inventory	$1.7B-4.3%	$1.8B+18.6%	$1.5B-6.9%	$1.6B-3.9%	$1.7B+82.5%	$922.0M
Accounts Receivable	$4.4B-5.2%	$4.7B-2.4%	$4.8B+6.3%	$4.5B-8.2%	$4.9B+36.6%	$3.6B
Goodwill	$8.3B0.0%	$8.3B0.0%	$8.3B-0.2%	$8.3B+2.8%	$8.1B+96.9%	$4.1B
Total Liabilities	$39.7B+0.7%	$39.4B-6.2%	$42.0B-10.5%	$46.9B-6.6%	$50.2B+28.8%	$39.0B
Current Liabilities	$12.0B+6.4%	$11.3B+0.4%	$11.2B-3.2%	$11.6B+1.9%	$11.4B+16.8%	$9.8B
Long-Term Debt	$24.9B+7.4%	$23.2B+1.0%	$23.0B-8.8%	$25.2B-12.1%	$28.6B+29.7%	$22.1B
Total Equity	$19.3B-15.0%	$22.7B+7.3%	$21.2B+0.7%	$21.1B+15.6%	$18.2B-19.6%	$22.6B
Retained Earnings	$11.5B-29.5%	$16.3B+3.9%	$15.7B-3.9%	$16.3B+13.5%	$14.4B-25.8%	$19.4B

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$58.5B+5.0%	$55.7B-1.3%	$56.4B-4.3%	$59.0B+8.2%	$54.5B+1.8%	$53.6B-4.8%	$56.3B-9.4%	$62.1B
Current Assets	$17.9B+21.4%	$14.7B-12.9%	$16.9B-11.8%	$19.2B+29.7%	$14.8B+20.0%	$12.3B-12.3%	$14.0B-12.7%	$16.1B
Cash & Equivalents	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	$1.8B-2.2%	$1.8B+3.8%	$1.8B+2.9%	$1.7B-8.5%	$1.9B-7.7%	$2.0B+9.3%	$1.9B+3.7%	$1.8B
Accounts Receivable	$5.1B+6.6%	$4.8B+9.0%	$4.4B-0.7%	$4.4B-3.6%	$4.6B-1.6%	$4.7B-0.1%	$4.7B+0.2%	$4.7B
Goodwill	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B
Total Liabilities	$37.0B+2.4%	$36.1B-3.3%	$37.4B-5.8%	$39.7B+9.8%	$36.1B+2.1%	$35.4B-8.9%	$38.8B-1.4%	$39.4B
Current Liabilities	$12.3B+9.9%	$11.2B-9.4%	$12.3B+2.8%	$12.0B+2.4%	$11.7B+8.8%	$10.8B-17.2%	$13.0B+15.4%	$11.3B
Long-Term Debt	$22.1B0.0%	$22.1B0.0%	$22.1B-11.0%	$24.9B+16.1%	$21.4B-0.5%	$21.5B+0.1%	$21.5B-7.2%	$23.2B
Total Equity	$21.5B+10.0%	$19.6B+2.7%	$19.1B-1.3%	$19.3B+5.1%	$18.4B+1.1%	$18.2B+4.3%	$17.5B-23.3%	$22.7B
Retained Earnings	$12.8B+13.2%	$11.3B+3.6%	$10.9B-4.9%	$11.5B+3.8%	$11.1B-0.8%	$11.2B+4.8%	$10.7B-34.6%	$16.3B

GILD Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	$10.8B+35.2%	$8.0B-11.8%	$9.1B-20.3%	$11.4B+39.4%	$8.2B-10.7%	$9.1B
Capital Expenditures	$523.0M-10.6%	$585.0M-19.6%	$728.0M+25.7%	$579.0M-10.9%	$650.0M-21.2%	$825.0M
Free Cash Flow	$10.3B+38.9%	$7.4B-11.1%	$8.3B-22.8%	$10.8B+43.7%	$7.5B-9.6%	$8.3B
Investing Cash Flow	-$3.4B-52.3%	-$2.3B+8.2%	-$2.5B+21.2%	-$3.1B+78.6%	-$14.6B-87.0%	-$7.8B
Financing Cash Flow	-$3.4B+33.0%	-$5.1B+20.8%	-$6.5B+27.1%	-$8.9B-1252.9%	$770.0M+110.1%	-$7.6B
Dividends Paid	$3.9B+2.9%	$3.8B+2.7%	$3.7B+2.9%	$3.6B+4.5%	$3.4B+7.0%	$3.2B
Share Buybacks	$1.1B+15.0%	$1.0B-28.4%	$1.4B+155.7%	$546.0M-65.5%	$1.6B-9.5%	$1.7B

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	$1.8B	N/A	N/A	N/A	$2.2B	N/A
Capital Expenditures	N/A	N/A	$104.0M	N/A	N/A	N/A	$105.0M	N/A
Free Cash Flow	N/A	N/A	$1.7B	N/A	N/A	N/A	$2.1B	N/A
Investing Cash Flow	N/A	N/A	-$415.0M	N/A	N/A	N/A	-$2.2B	N/A
Financing Cash Flow	N/A	N/A	-$3.4B	N/A	N/A	N/A	-$1.4B	N/A
Dividends Paid	$995.0M-0.2%	$997.0M-1.3%	$1.0B	N/A	$977.0M-0.1%	$978.0M-1.2%	$990.0M	N/A
Share Buybacks	N/A	N/A	$730.0M	N/A	N/A	N/A	$400.0M	N/A

GILD Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	78.3%+2.2pp	76.0%-3.2pp	79.3%+3.4pp	75.8%-5.7pp	81.5%+2.3pp	79.2%
Operating Margin	5.8%-22.3pp	28.1%+1.2pp	26.9%-9.5pp	36.3%+19.8pp	16.5%-2.6pp	19.1%
Net Margin	1.7%-19.2pp	20.9%+4.1pp	16.8%-6.0pp	22.8%+22.3pp	0.5%-23.5pp	24.0%
Return on Equity	2.5%-22.4pp	24.9%+3.3pp	21.6%-7.9pp	29.5%+28.9pp	0.7%-23.1pp	23.8%
Return on Assets	0.8%-8.3pp	9.1%+1.9pp	7.3%-1.9pp	9.2%+9.0pp	0.2%-8.6pp	8.7%
Current Ratio	1.60+0.2	1.43+0.1	1.29+0.0	1.27-0.1	1.40-1.7	3.10
Debt-to-Equity	1.29+0.3	1.02-0.1	1.08-0.1	1.20-0.4	1.57+0.6	0.98
FCF Margin	35.8%+8.5pp	27.4%-3.2pp	30.6%-9.0pp	39.6%+9.1pp	30.4%-6.6pp	37.1%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	79.8%+1.0pp	78.8%+1.9pp	76.9%	N/A	79.1%+1.3pp	77.8%+1.0pp	76.8%	N/A
Operating Margin	42.8%+7.9pp	34.9%+1.4pp	33.6%	N/A	11.8%-26.2pp	38.0%+102.7pp	-64.6%	N/A
Net Margin	39.3%+11.6pp	27.7%+8.0pp	19.7%	N/A	16.6%-6.6pp	23.2%+85.6pp	-62.4%	N/A
Return on Equity	14.2%+4.2pp	10.0%+3.1pp	6.9%	N/A	6.8%-2.1pp	8.9%	N/A	N/A
Return on Assets	5.2%+1.7pp	3.5%+1.2pp	2.3%	N/A	2.3%-0.7pp	3.0%+10.4pp	-7.4%	N/A
Current Ratio	1.45+0.1	1.32-0.1	1.37-0.2	1.60+0.3	1.26+0.1	1.14+0.1	1.08-0.3	1.43
Debt-to-Equity	1.03-0.1	1.13-0.0	1.16-0.1	1.29+0.1	1.17-0.0	1.18-0.0	1.23+0.2	1.02
FCF Margin	N/A	N/A	24.8%	N/A	N/A	N/A	31.6%	N/A

Frequently Asked Questions

What is Gilead Sciences Inc's annual revenue?

Gilead Sciences Inc (GILD) reported $28.8B in revenue for fiscal year 2024.

How fast is Gilead Sciences Inc's revenue growing?

Gilead Sciences Inc (GILD) revenue grew by 6% year-over-year, from $27.1B to $28.8B in fiscal year 2024.

Is Gilead Sciences Inc profitable?

Yes, Gilead Sciences Inc (GILD) reported a net income of $480.0M in fiscal year 2024, with a net profit margin of 1.7%.

What is Gilead Sciences Inc's EBITDA?

Gilead Sciences Inc (GILD) had EBITDA of $4.4B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Gilead Sciences Inc's gross margin?

Gilead Sciences Inc (GILD) had a gross margin of 78.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Gilead Sciences Inc's operating margin?

Gilead Sciences Inc (GILD) had an operating margin of 5.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Gilead Sciences Inc's net profit margin?

Gilead Sciences Inc (GILD) had a net profit margin of 1.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Does Gilead Sciences Inc pay dividends?

Yes, Gilead Sciences Inc (GILD) paid $3.08 per share in dividends during fiscal year 2024.

What is Gilead Sciences Inc's return on equity (ROE)?

Gilead Sciences Inc (GILD) has a return on equity of 2.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Gilead Sciences Inc's free cash flow?

Gilead Sciences Inc (GILD) generated $10.3B in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Gilead Sciences Inc's operating cash flow?

Gilead Sciences Inc (GILD) generated $10.8B in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Gilead Sciences Inc's total assets?

Gilead Sciences Inc (GILD) had $59.0B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Gilead Sciences Inc's capital expenditures?

Gilead Sciences Inc (GILD) invested $523.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Gilead Sciences Inc spend on research and development?

Gilead Sciences Inc (GILD) invested $5.9B in research and development during fiscal year 2024.

Does Gilead Sciences Inc buy back shares?

Yes, Gilead Sciences Inc (GILD) spent $1.1B on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Gilead Sciences Inc have outstanding?

Gilead Sciences Inc (GILD) had 1.25B shares outstanding as of fiscal year 2024.

What is Gilead Sciences Inc's current ratio?

Gilead Sciences Inc (GILD) had a current ratio of 1.60 as of fiscal year 2024, which is generally considered healthy.

What is Gilead Sciences Inc's debt-to-equity ratio?

Gilead Sciences Inc (GILD) had a debt-to-equity ratio of 1.29 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Gilead Sciences Inc's return on assets (ROA)?

Gilead Sciences Inc (GILD) had a return on assets of 0.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.